Novel benzimidazole-based azine derivatives as potent urease inhibitors: synthesis, in vitro and in silico approach.

IF 3.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Future medicinal chemistry Pub Date : 2024-09-23 DOI:10.1080/17568919.2024.2401311
Hamidullah, Aftab Alam, Ahmed A Elhenawy, Mumtaz Ali, Abdul Latif, Ajmal Khan, Ahmed Al-Harrasi, Manzoor Ahmad
{"title":"Novel benzimidazole-based azine derivatives as potent urease inhibitors: synthesis, <i>in vitro</i> and <i>in silico</i> approach.","authors":"Hamidullah, Aftab Alam, Ahmed A Elhenawy, Mumtaz Ali, Abdul Latif, Ajmal Khan, Ahmed Al-Harrasi, Manzoor Ahmad","doi":"10.1080/17568919.2024.2401311","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> In light of various biological activities of benzimidazole and azines, this study focuses on reporting novel derivatives of benzimidazole nucleus.<b>Methods:</b> Twenty novel azines of benzimidazole were synthesized, characterized and tested for <i>in vitro</i> urease inhibitory activity.<b>Results:</b> All these derivatives showed excellent to good inhibition in the range of IC<sub>50</sub> values 14.21 ± 1.87 to 76.11 ± 1.81 μM by comparing with standard thiourea 21.14 ± 0.42 μM. Docking studies were performed for the targeted benzimidazole derivatives to understand the binding mechanics. The results indicated higher binding efficacy compared with the reference inhibitor.<b>Conclusion:</b> This work identifies potential lead candidates for novel urease inhibitors, which with industrial support may be harnessed for the development of new drugs.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2401311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: In light of various biological activities of benzimidazole and azines, this study focuses on reporting novel derivatives of benzimidazole nucleus.Methods: Twenty novel azines of benzimidazole were synthesized, characterized and tested for in vitro urease inhibitory activity.Results: All these derivatives showed excellent to good inhibition in the range of IC50 values 14.21 ± 1.87 to 76.11 ± 1.81 μM by comparing with standard thiourea 21.14 ± 0.42 μM. Docking studies were performed for the targeted benzimidazole derivatives to understand the binding mechanics. The results indicated higher binding efficacy compared with the reference inhibitor.Conclusion: This work identifies potential lead candidates for novel urease inhibitors, which with industrial support may be harnessed for the development of new drugs.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
作为强效脲酶抑制剂的新型苯并咪唑基嗪衍生物:合成、体外和硅学方法。
目的:鉴于苯并咪唑和叠氮的各种生物活性,本研究重点报道了苯并咪唑核的新型衍生物:方法:对 20 种新型苯并咪唑叠氮化物进行了合成、表征和体外脲酶抑制活性测试:结果:与标准硫脲 21.14 ± 0.42 μM 相比,所有这些衍生物都表现出极好的抑制作用,IC50 值范围在 14.21 ± 1.87 到 76.11 ± 1.81 μM 之间。对目标苯并咪唑衍生物进行了 Docking 研究,以了解其结合机理。结果表明,与参考抑制剂相比,苯并咪唑衍生物具有更高的结合效力:本研究发现了新型脲酶抑制剂的潜在候选先导化合物,在工业界的支持下可用于新药开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
期刊最新文献
Current landscape of tropomyosin receptor tyrosine kinase inhibitors. Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme. Novel benzimidazole-based azine derivatives as potent urease inhibitors: synthesis, in vitro and in silico approach. Organotellurium (IV) complexes as anti-malarial agents: synthesis, characterization and computational insights. Exploring biological activities of novel Schiff bases derived from amlodipine and in silico molecular modeling studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1